186 related articles for article (PubMed ID: 37855056)
1. Talquetamab in multiple myeloma.
Liu L; Krishnan A
Haematologica; 2024 Mar; 109(3):718-724. PubMed ID: 37855056
[TBL] [Abstract][Full Text] [Related]
2. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
Chari A; Minnema MC; Berdeja JG; Oriol A; van de Donk NWCJ; Rodríguez-Otero P; Askari E; Mateos MV; Costa LJ; Caers J; Verona R; Girgis S; Yang S; Goldsmith RB; Yao X; Pillarisetti K; Hilder BW; Russell J; Goldberg JD; Krishnan A
N Engl J Med; 2022 Dec; 387(24):2232-2244. PubMed ID: 36507686
[TBL] [Abstract][Full Text] [Related]
3. BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms.
Lee H; Neri P; Bahlis NJ
Blood; 2024 Mar; 143(13):1211-1217. PubMed ID: 38194680
[TBL] [Abstract][Full Text] [Related]
4. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
Landgren O; Nadeem O
Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
[TBL] [Abstract][Full Text] [Related]
5. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
Granger K; Gaffney KJ; Davis JA
J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
[TBL] [Abstract][Full Text] [Related]
6. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
Zhao J; Ren Q; Liu X; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
[TBL] [Abstract][Full Text] [Related]
7. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.
Verkleij CPM; Broekmans MEC; van Duin M; Frerichs KA; Kuiper R; de Jonge AV; Kaiser M; Morgan G; Axel A; Boominathan R; Sendecki J; Wong A; Verona RI; Sonneveld P; Zweegman S; Adams HC; Mutis T; van de Donk NWCJ
Blood Adv; 2021 Apr; 5(8):2196-2215. PubMed ID: 33890981
[TBL] [Abstract][Full Text] [Related]
8. MonumenTAL Results for Talquetamab in Myeloma.
Cancer Discov; 2023 Feb; 13(2):250-251. PubMed ID: 36508587
[TBL] [Abstract][Full Text] [Related]
9. Targeting GPRC5D in multiple myeloma.
Elemian S; Al Hadidi S
Expert Rev Anticancer Ther; 2024 May; 24(5):229-238. PubMed ID: 38607646
[TBL] [Abstract][Full Text] [Related]
10. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
[TBL] [Abstract][Full Text] [Related]
11. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Rodriguez-Otero P; van de Donk NWCJ; Pillarisetti K; Cornax I; Vishwamitra D; Gray K; Hilder B; Tolbert J; Renaud T; Masterson T; Heuck C; Kane C; Verona R; Moreau P; Bahlis N; Chari A
Blood Cancer J; 2024 Feb; 14(1):24. PubMed ID: 38307865
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience.
Dima D; Davis JA; Ahmed N; Jia X; Sannareddy A; Shaikh H; Shune L; Kaur G; Khouri J; Afrough A; Strouse C; Lochner J; Mahmoudjafari Z; Raza S; Valent J; Anderson LD; Anwer F; Abdallah AO; Hashmi H
Transplant Cell Ther; 2024 Mar; 30(3):308.e1-308.e13. PubMed ID: 38151105
[TBL] [Abstract][Full Text] [Related]
13. An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma.
Firestone R; Lesokhin AM; Usmani SZ
Blood Cancer Discov; 2023 Nov; 4(6):433-436. PubMed ID: 37824758
[TBL] [Abstract][Full Text] [Related]
14. Teclistamab in Relapsed or Refractory Multiple Myeloma.
Moreau P; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Nooka AK; Martin T; Rosinol L; Chari A; Karlin L; Benboubker L; Mateos MV; Bahlis N; Popat R; Besemer B; Martínez-López J; Sidana S; Delforge M; Pei L; Trancucci D; Verona R; Girgis S; Lin SXW; Olyslager Y; Jaffe M; Uhlar C; Stephenson T; Van Rampelbergh R; Banerjee A; Goldberg JD; Kobos R; Krishnan A; Usmani SZ
N Engl J Med; 2022 Aug; 387(6):495-505. PubMed ID: 35661166
[TBL] [Abstract][Full Text] [Related]
15. Talquetamab: First Approval.
Keam SJ
Drugs; 2023 Oct; 83(15):1439-1445. PubMed ID: 37792138
[TBL] [Abstract][Full Text] [Related]
16. The emerging therapeutic landscape of relapsed/refractory multiple myeloma.
Tanenbaum B; Miett T; Patel SA
Ann Hematol; 2023 Jan; 102(1):1-11. PubMed ID: 36462062
[TBL] [Abstract][Full Text] [Related]
17. Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab.
Laheij AMGA; van de Donk NWCJ
Support Care Cancer; 2023 Dec; 32(1):20. PubMed ID: 38092979
[TBL] [Abstract][Full Text] [Related]
18. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.
Einsele H; Moreau P; Bahlis N; Bhutani M; Vincent L; Karlin L; Perrot A; Goldschmidt H; van de Donk NWCJ; Ocio EM; Martinez-Lopez J; Rodríguez-Otero P; Dytfeld D; Diels J; Strulev V; Haddad I; Renaud T; Ammann E; Cabrieto J; Perualila N; Gan R; Zhang Y; Parekh T; Albrecht C; Weisel K; Mateos MV
Adv Ther; 2024 Apr; 41(4):1576-1593. PubMed ID: 38402374
[TBL] [Abstract][Full Text] [Related]
19. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
Martin TG; Mateos MV; Nooka A; Banerjee A; Kobos R; Pei L; Qi M; Verona R; Doyle M; Smit J; Sun W; Trancucci D; Uhlar C; van de Donk NWCJ; Rodriguez C
Cancer; 2023 Jul; 129(13):2035-2046. PubMed ID: 36991547
[TBL] [Abstract][Full Text] [Related]
20. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Nooka AK; Rodriguez C; Mateos MV; Manier S; Chastain K; Banerjee A; Kobos R; Qi K; Verona R; Doyle M; Martin TG; van de Donk NWCJ
Cancer; 2024 Mar; 130(6):886-900. PubMed ID: 37960969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
